Acalabrutinib

Acalabrutinib CAS NO.1420477-60-6

Min.Order: 0 Metric Ton
Payment Terms:

Product Details

Keywords

Bruton Tyrosine Kinase (BTK) inhibitor
Antineoplastics
ACP-196

Quick Details

ProName: Acalabrutinib
CasNo: 1420477-60-6
Molecular Formula: C26H23N7O2
Application: Antineoplastics MCL blood cancers
ProductionCapacity: Metric Ton/Day
Purity: 99%
LimitNum: 0 Metric Ton

Superiority

We supply Acalabrutinib with high purity and competitive price

This is Xiang from Holypharm biotech co., ltd, we are pharmaceutical corporation with complete industry chain of research, development, production and marketing.As for some projects we also can provide technical support.
We supply API for many high-end market with high quality and competitive price, as well as co-operating with MSDand Merck CO., LTD.

Details

To date, acalabrutinib has been used in trials studying the treatment of B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, and Hodgkin Lymphoma, among others.

As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib) medication as a Bruton Tyrosine Kinase (BTK) inhibitor indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have already received at least one prior therapy, marking the company's first entry into the treatment of blood cancers.

HANGZHOU HOLYPHARM BIOTECH CO.,LTD